Published on 18/12/2025
J-CTD Made Practical: How to Structure, Author, and Publish Japan-Ready CTD Dossiers
CTD vs J-CTD: What’s the Same, What’s Different, and Why It Matters
The Common Technical Document (CTD) gives sponsors a shared spine for global submissions, but each region overlays its own conventions where national law and practice require it. Japan’s implementation—commonly referred to as the Japanese CTD (J-CTD)—retains the CTD’s five-module architecture while adding jurisdiction-specific content, language, and publishing rules that directly affect review time. The scientific core of Modules 2–5 remains aligned with ICH; the differentiators are how you present the science for Japanese reviewers, in Japanese, and with artifacts that behave predictably in local systems. That is why success in Japan is rarely a matter of “copy, translate, paste.” It is a deliberate localization project that starts at planning, not at publishing week.
Two principles anchor J-CTD authoring. First, decision-first communication: each summary should lead with the regulatory claim you seek and the two or three analyses that prove it, pointing explicitly to leaves where the decisive tables live. Second, identity and language control: Japanese names/addresses for the Marketing Authorization Holder (MAH) and manufacturers, specification/method titles, and
Understanding J-CTD therefore means understanding not only what content belongs in each module, but also how the module must be written in Japanese, how it must be hyperlinked, what proof points Japanese reviewers expect to see, and how those points map to Japan’s operational realities (GQP/GVP, re-examination, lot release, pricing sequences). The CTD spine is global; J-CTD is the art and discipline of making that spine native to Japan’s review ecosystem led by the Pharmaceuticals and Medical Devices Agency (PMDA) and authorized by the Ministry of Health, Labour and Welfare (MHLW).
Module 1 in Japan: Forms, MAH Identity, Labeling (PI), and Jurisdictional Artifacts
Module 1 is where J-CTD diverges most visibly from other regions. It contains Japan-specific forms, letters of authorization, MAH information, Foreign Manufacturer Accreditation (for overseas sites), GQP/GVP documentation, and Japanese labeling—the Package Insert (PI) in both clean and tracked form. Reviewers expect crisp alignment between Module 1 identities and everything else in the file: exact Japanese company names and addresses, license numbers, manufacturer identifiers, and the way strength/dosage form are rendered in Japanese on both PI and certificates. A stray punctuation mark or inconsistent character can trigger clock-stops because it implies the legal persona is ambiguous.
The most robust Module 1s are built from a single source of truth. They leverage a controlled glossary and translation memory so that recurring terms (dosage forms, manufacturing steps, risk statements) do not drift between the PI, RMP, and Module 2 summaries. They also include Japan-ready inspection packets—GMP, GCP, and GLP readiness summaries with Japanese titles, and, when applicable, proof of Foreign Manufacturer Accreditation in order. For lifecycle predictability, many sponsors now include a brief Module 1 narrative that cross-walks established conditions (if using ICH Q12 logic) to Japanese specification and method titles; this helps reviewers see how future variations will be controlled.
Finally, Module 1 is where publishing hygiene shows. PMDA expects selectable text (not scans) for core content, PDF/A conformance, and embedded Japanese fonts. Bookmarks and leaf titles should be in Japanese where reviewers navigate most. Sponsors who treat Module 1 as a living contract—identity, labeling, safety operations, and inspection readiness—consistently see fewer administrative queries and smoother transitions to MHLW authorization.
Module 2 for Japan: Decision-First Summaries that Point to Proof—In Japanese
While the structure of Module 2 mirrors other ICH regions, J-CTD requires Japanese-language summaries that do more than paraphrase. They must lead reviewers to decisions. For quality, start with a transparent CQA register and control strategy narrative that maps attributes to process parameters via risk assessment, then point to the exact Module 3 leaves (e.g., PPQ results, stability overlays, impurity control tables). If you claim a design space or proven acceptable ranges, cite the leaf IDs with the defining experiments and acceptance criteria, and explain robustness in Japanese. Where lifecycle tools are pivotal (established conditions, comparability protocols), summarize them succinctly and hyperlink to their full text.
On the clinical side, Module 2 should translate global evidence into Japanese applicability. If efficacy relies on MRCTs, preface with subgroup/sensitivity analyses that include Japanese patients or justify bridging through exposure–response and population PK/PD. Align endpoints and comparators with Japanese standard-of-care, and state estimands clearly (treatment-policy vs hypothetical for common intercurrent events). Safety narratives must anticipate GVP and RMP commitments in Japan, explaining how risks will be minimized in local care settings. Reviewers value concision paired with navigation: decision → proof → link. Repeating entire clinical study reports in prose slows the read and invites redundant questions.
Stylistically, enforce bilingual discipline for tables and figures that are frequently cited across sections: Japanese titles and footnotes, consistent units and symbols, and embedded fonts that render on agency machines. A one-page “click map” at the start of Module 2—in Japanese—routing to the three or four decisive artifacts (e.g., PPQ table, stability overlay, efficacy forest plot, key safety table) often halves the time to the first substantive query.
Module 3 (CMC): Japan-Operable Control Strategy, Method Portability, and Lifecycle Clarity
In J-CTD, Module 3 carries the same science as elsewhere but must demonstrate that the control strategy is operable in Japan. Start with a CQA register linked to process parameters, then provide either a design space or proven acceptable ranges with evidence. For PPQ, present commercial-scale data (Cpk/Ppk for critical attributes) at the site(s) intended for Japan supply. Stability should reflect Japanese distribution realities (temperature/humidity profiles, transport simulations when relevant), and method validation should prove portability on equipment and columns widely available in Japanese QC labs. When impurity control invokes ICH M7 and Q3D, localize inputs—actual suppliers for Japan, packaging used on Japanese lines—so reviewers can see sustainability beyond approval.
Localization extends to titles and language. Specifications, test names, and method titles should be in Japanese and match the terms used on the PI, batch documentation exemplars, and CoAs. If you reference compendial methods (e.g., JP/EP/USP), show how they are implemented in Japanese labs and justify any differences. For biologics, present comparability data that link process changes to potency and glycan profiles; for small molecules, show fate-and-purge rationales with edge-of-failure demonstrations. If you intend to leverage ICH Q12, include a table of established conditions and the comparability protocols you plan to use; executed examples build trust and shorten post-approval timelines.
Two publishing practices de-risk Module 3. First, create a standards matrix mapping each applicable standard (JP, ICH, internal SOPs) to test methods, acceptance criteria, and leaf IDs. Second, ensure every Japanese term that appears in Module 3 appears identically in Module 1 labeling and in the RMP where safety-related specs matter. This is identity governance; it prevents drift across modules and keeps review focused on science, not proofreading.
Module 4–5: Nonclinical and Clinical Evidence Tailored for Japanese Reviewers
Module 4 (nonclinical) is typically portable, but your summaries should call out any species/strain choices that intersect with Japanese expectations and any endpoints where Japanese guidelines or practice differ. Ensure figure/table titles are bilingual where cited in Module 2. Provide cross-links from Module 2 nonclinical summaries directly to the pivotal tox tables and safety pharmacology results, so reviewers can land on decision-grade evidence in one click.
Module 5 (clinical) is where Japanese applicability must be explicit. For MRCTs, include subgroup analyses for Japanese patients and sensitivity analyses that reflect Japanese care patterns. For bridging approaches, show the chain of inference: Japanese PK/PD → exposure–response → dose justification → safety margin translation. If registrational evidence relies on real-world data, describe Japanese data provenance, curation, and bias control; data integrity standards do not loosen in translation. Present estimands aligned with how intercurrent events are handled in Japan (e.g., rescue meds), and justify comparator choices against Japanese clinical guidelines.
Keep Module 5 navigable: Japanese bookmarks for study reports, standard file-naming conventions, hyperlinks from Module 2 to CSR tables/figures, and traceable derivations for key analyses. Avoid scanned text; use selectable PDFs with embedded fonts so agency systems index and render correctly. When done well, Module 5 allows reviewers to move from a Japanese claim sentence in Module 2 to the underlying statistics and patient-level context without friction.
Japan eCTD Publishing: Fonts, Bookmarks, Leaf Titles, and Identity Reconciliation
Many “translation issues” in Japan are actually publishing defects. J-CTD eCTD hygiene is therefore a core competency, not a clerical afterthought. Enforce PDF/A across all leaves; embed Japanese fonts to prevent missing glyphs; avoid scanned images except for legalized certificates (which should be paired with selectable Japanese translations). Build deterministic Japanese bookmarks and leaf titles that mirror section headings, and verify internal hyperlinks across Modules 2–5. Before submission, run a T-60/T-14 gate that produces three artifacts: (1) a font-embedding report, (2) a bookmark inventory matched to your dossier map, and (3) an identity reconciliation that compares MAH/manufacturer names/addresses, method/spec titles, and strength/dosage-form phrasing across Module 1 forms, labels, certificates, and Module 3/5 references.
File structure matters. Use naming conventions that are stable and informative to Japanese readers (e.g., “M2_QOS_CMC_DesignSpace_ja.pdf”). Ensure that your cover letter in Japanese includes a click-map to decisive evidence: PPQ summary, stability overlay, impurity control tables, pivotal efficacy/safety results, and tracked→clean PI changes. Sponsors who deliver this map reduce the back-and-forth that often occurs when reviewers have to hunt for proof.
Finally, remember that eCTD quality signals operational maturity. If your PDFs render cleanly, maps resolve instantly, and identity aligns across modules, reviewers can trust that your post-approval controls (GQP/GVP, RMP, label governance) will also be disciplined. That trust shortens cycles.
Crosswalking Global CTD to J-CTD: A Repeatable Process for Multiregional Programs
Global programs that treat J-CTD as a late translation sprint pay for it in queries. A better approach is to run a structured crosswalk from the start. Step 1: lock a Japanese glossary and translation memory seeded with accepted terms from prior approvals. Step 2: build a Module 2 decision grid that lists each regulatory claim and the exact Japanese sentences, tables, and figures that will support it. Step 3: create a Module 3 localization plan (supplier lists for Japan, method portability studies, stability profiles for Japanese logistics) and schedule PPQ so Japanese-intended sites and materials are visible pre-submission. Step 4: author the PI in Japanese in parallel, keeping clean and tracked versions under change control and aligning warnings/contraindications with RMP commitments. Step 5: implement a T-60/T-14 eCTD gate with pass/fail criteria (fonts, bookmarks, hyperlinks, identity).
Use governance to make the crosswalk stick. Establish a monthly Japan board with Regulatory, CMC, Clinical/Biostats, PV/Medical, Quality, and Market Access, sharing a dashboard that tracks query readiness, inspection packets, label go-live plans, and price-listing milestones. Tie meeting minutes to dossier edits so consultation guidance becomes Module 2 text and Module 3 tables—not just action items that drift into inboxes. The payoff is predictability: fewer queries, faster resolution, and post-approval changes that flow through established conditions and comparability protocols without re-litigation.
For organizations submitting to multiple ICH regions in parallel, codify a “J-CTD delta kit” in your authoring system: Japanese glossary, standard Module 1 forms, PI templates, eCTD naming conventions, click-map cover letter templates, and identity diff scripts. Reuse accelerates speed while enforcing consistency.
Common Pitfalls and Field-Tested Fixes for J-CTD Submissions
Identity drift: mismatched Japanese names/addresses or method/spec titles across forms, labels, and dossier leaves. Fix: single source of truth; automated diffs; final manual Japanese read-through for punctuation and spacing.
Method non-portability: analytical procedures validated on consumables not widely available in Japan. Fix: method robustness on locally available columns/reagents; system-suitability ranges that anticipate variability; explicit mapping to JP where applicable.
Weak lifecycle story: citing ICH Q12 without implemented established conditions or comparability protocols. Fix: define ECs, draft protocols early, execute at least one example pre-NDA, hyperlink results in Module 3.
Japanese applicability gaps: MRCT evidence presented without Japanese subgroup/sensitivity analyses or bridging. Fix: estimands aligned to Japanese practice; exposure–response modeling; focused Japanese PK; comparator justification against Japanese guidelines.
Publishing defects: non-embedded fonts, scanned text, unstable bookmarks/hyperlinks. Fix: PDF/A with embedded Japanese fonts; deterministic bookmarks; T-60/T-14 publishing gates; hyperlink integrity checks.
Late labeling: PI drafted at the end, causing negotiation churn and misalignment with RMP. Fix: author Japanese PI in parallel with Module 2; maintain clean/tracked versions; keep a label-consequences log to propagate changes to artwork and distributor notifications.